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Abstract. Viral vector-mediated expression of genes (e.g., coding for opsins and designer receptors) has grown
increasingly popular. Cell-type specific expression is achieved by altering viral vector tropism through cross-
packaging or by cell-specific promoters driving gene expression. Detailed information about transduction proper-
ties of most recombinant adeno-associated viral vector (rAAV) serotypes in macaque cortex is gradually
becoming available. Here, we compare transduction efficiencies and expression patterns of reporter genes
in two macaque neocortical areas employing different rAAV serotypes and promoters. A short version of the
calmodulin-kinase-II (CaMKIIα0.4) promoter resulted in reporter gene expression in cortical neurons for all tested
rAAVs, albeit with different efficiencies for spread: rAAV2/5>>rAAV2/7>rAAV2/8>rAAV2/9>>rAAV2/1 and pro-
portion of transduced cells: rAAV2/1>rAAV2/5>rAAV2/7=rAAV2/9>rAAV2/8. In contrast to rodent studies, the
cytomegalovirus (CMV) promoter appeared least efficient in macaque cortex. The human synapsin-1 promoter
preceded by the CMV enhancer (enhSyn1) produced homogeneous reporter gene expression across all layers,
while two variants of the CaMKIIα promoter resulted in different laminar transduction patterns and cell speci-
ficities. Finally, differences in expression patterns were observed when the same viral vector was injected in two
neocortical areas. Our results corroborate previous findings that reporter-gene expression patterns and effi-
ciency of rAAV transduction depend on serotype, promoter, cortical layer, and area. © The Authors. Published by
SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution
of the original publication, including its DOI. [DOI: 10.1117/1.NPh.2.3.031209]
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1 Introduction
For more than three decades, viral vectors have been used exten-
sively to deliver genetic material into specific subsets of cells
throughout the body, with the ultimate goal of human gene
therapy.1–5 To this end, recombinant viral vectors containing
genes-of-interest and free of replication-essential elements have
been bioengineered. Presently, such viral vectors are also widely
used in basic biomedical research to express proteins in well-
defined cell types.6
In neuroscience, several methods have recently been intro-
duced to control neural activity with unprecedented specificity.
Methods such as optogenetics,7–11 “designer receptors exclu-
sively activated by designer drugs” (in short, DREADD) 12–14
and the double-infection technique (DIT),15,16 rely mainly on
viral vectors to introduce genes encoding light-sensitive proteins
(opsins), artificial receptors (DREADD), or neurotoxins (DIT)
into neurons. Transduction of specific subsets of cells (i.e., tro-
pism) is inherent to the viral vector used and depends on the
interaction between viral vector envelope/capsid and receptors
on the cell membrane. Subsequent reporter or transgene expres-
sion depends on the potency of the heterologous promoter and
the availability of transcription factors (TFs) for this promoter in
the targeted cell (cell specificity).17 Despite the abundant use of
viral vectors, state-of-the-art neuroscience and clinical studies
have exposed potential challenges. These include cross-species
variation in vector tissue tropism and gene transfer efficiency,
pre-existing humoral immunity to capsids, and vector dose-de-
pendent toxicity in animal models and patients. Detailed infor-
mation about the transduction characteristics of such vector
systems in macaque neocortex, however, is only sparsely avail-
able.18 This is particularly an issue considering the increasing
popularity of viral vectors in nonhuman primate research.
The most frequently used viral expression systems are devel-
oped from adenoviruses, adeno-associated virus (AAV), herpes
simplex virus, gamma retroviruses and lentiviruses (LV; subclass
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of retroviruses), each having their particular advantages and lim-
itations.1,19 AAVand LVare most often used in the central nervous
system (CNS) since they are relatively easy to produce and evoke
minimal immune responses.17,19 The packing capacity of AAV is
low compared to LV, and genes delivered using AAV vectors do
remain episomal in the transduced cell. Although LVs showed
long-lasting expression2,20 and were clinically successful in sev-
eral primate studies,21,22 AAV is considered to be more appealing
for transgene expression in CNS. AAV is small (20 to 25 nm),
nonenveloped, single-stranded DNA parvoviruses.23 They are
known for their efficient neuronal (NeuN) transduction, long-last-
ing transgene expression (up to 2 years in rodents and 6 years
in primates) and safety profile (no integration in host-cell
genome).3,24–28 In addition, they can transduce both dividing
and nondividing cells. The best-characterized AAV serotype,
first cloned into bacterial plasmids, is AAV serotype 2 carrying
an AAV2-derived genome (AAV2/2).29 Through cross-packag-
ing, AAV2-based genomes can be packaged in alternative
AAV serotypes (e.g., rAAV2/5), which yields higher transduction
efficiencies than AAV2/2. AAV-based vectors are currently the
most widely used for preclinical research, due to favorable char-
acteristics such as higher transduction efficiencies and greater
dispersion.30–32 Unfortunately, the latter properties are species
specific and even brain region specific.30,33 Moreover, informa-
tion about transduction and expression properties obtained in
rodents does not always translate to primates.34–38 In macaque
monkeys, a comparison between the transduction properties of
different rAAVs in subcortical structures, including the substantia
nigra, striatum,39,40 and basal ganglia,41 revealed that rAAV2/1
and rAAV2/5 were most efficient when under the control of a
synthetic chicken ß-actin promoter. In addition, another study
of Sanchez et al.40 revealed a three- to fourfold higher efficiency
of rAAV2/8 compared to rAAV2/1, 2/2, and 2/5 when using
a cytomegalovirus (CMV) promoter. Optogenetic studies in
macaques confirmed that viral vector transduction in cortex is
heterogenous across cortical layers.35,42,43 Recently, an exhaustive
comparison of transduction efficiencies of various recombinant
adeno-associated viral vector (rAAV) serotypes and promoters
in marmoset, mouse, and macaque neocortex again revealed
distinct transduction patterns depending on the serotype and
promoter used in the viral vector.18 Serotype rAAV2 showed a
smaller spread compared to rAAV1, 5, 8, and 9, while constructs
with the SynI promoter showed higher transgene expression in
layers 3 and 5 compared to CaMKII-constructs.
Therefore, to optimize future optogenetic, DREADD, and
DIT studies in macaque monkeys and to extend the results
obtained by Watakabe et al.,18 we determined the transduction
patterns of several rAAV serotypes using the CMV, two varia-
tions of the CaMKII, and the enhSyn1 promoters in macaque
cortex. Specifically, we investigated the efficiencies, laminar
expression patterns, spread, cell specificities and potential
antero- and/or retrograde projection properties of 12 different
rAAV vector/promoter combinations injected into primary vis-
ual and prefrontal cortex of rhesus monkeys, using immunohis-
tochemical evaluation of the reporter genes.
2 Materials and Methods
2.1 Subjects
Four hemispheres from the forebrains of two adult male rhesus
monkeys (Macaca mulatta) were used in this study (M10:
6.2 kg and M37: 6.5 kg). Prior to these terminal experiments,
both monkeys had participated in a series of electrophysiologi-
cal and/or contrast-agent enhanced functional magnetic reso-
nance imaging experiments unrelated to the present study.44
All experimental procedures were approved by the regulations
of the biosafety and ethical committees at KU Leuven and
strictly adhered to the guidelines of the National Institutes of
Health and the European guidelines for the care and use of lab-
oratory animals.
2.2 Vector Constructs
The recombinant AAV2 vectors used in this study were pack-
aged in AAV1, 5, 7, 8, 9 capsids (referred to as rAAV2/1, 2/5,
2/7, 2/8 and 2/9; Table 1). Expression of enhanced green
fluorescent protein (EGFP) or membrane localized cherry red
fluorescent protein (mCherry) was under the control of one of
four promoters: human CMV, human enhSyn1, Mus musculus
CaMKIIα0.4, or Mus musculus CaMKIIα1.3. Human enhSyn1
promoter was polymerase chain reaction (PCR) amplified from
a plasmid provided by Hioki et al.45 using ATTCTAGATAGTTA
TTAATAGTAATCAATTACGGGG as forward and AGGAT
CCCGCCGCAGCGCAG as reverse primer. The MmCa
MKIIα1.3 promoter was PCR amplified from plasmid 20944
(addgene) using following primers: Fw—AAAGCTAGC
CATTATGGCCTTAGGTCACTTCAT and Rev— AAAA
GCGCTGATATCCCGCTGCCCCCAGAACTAGGGGC. The
MmCaMKIIα0.4 fragment was amplified with—AAAGC
TAGCACTTGTGGACTAAGTTTGTTCACATCCC—as for-
ward and—AAAAGCGCTGATATCGCTGCCCCCAGAACT
AGGGGCCACTCG—as reverse primer. These PCR
fragments were ligated in the AAV transfer plasmid using
XbaI and BamHI for enhSyn1 and NheI and Eco47 III for
MmCaMKIIα after the hCMV promoter was cut out.
All vector constructs were generated by the Viral Vector Core
at KU Leuven according to published procedures.32 Briefly,
serum-free rAAV production was performed by triple transient
transfection of HEK 293T cells (ATCC, Manassas, Virginia)
using the AAV transfer plasmids, AAV rep/cap (2/1, 2/5,
2/7, 2/8, or 2/9) and pAd.DELTA.F6 plasmid in the ratio of
1:1:1 using polyethylenimine. The supernatant was harvested
5 days after transient transfection, concentrated using tangential
flow filtration, and purified using an iodixanol step gradient.
Gradient fractions were collected in 250 μl aliquots and fractions
with refraction indices between 1.39 and 1.42 were pooled. The
iodixanol of the pooled fractions was exchanged five times with
phosphate-buffered saline (PBS), in a Vivaspin 6 (PES, 100,000
MWCO, Sartorius AG, Goettingen, Germany). The resulting
concentrated rAAV was aliquoted and stored at −80°C.
Genomic titers that were determined as genomic copy num-
bers of the respective rAAV preparations were evaluated by
TaqMan-based quantitative PCR analysis using a primer
probe set for the polyA sequence (primer sequences, 5′-
TCTAGTTGCCAGCCATCTGTTGT-3′ and 5′-TGGGAGTGG
CACCTTCCA-3′; probe sequence, 5′-TCCCCCGTGCCTT
CCTTGACC–3′). Genome copies obtained for the different pro-
ductions ranged from 4.0 × 10e11 to 4.8 × 10e12 genome cop-
ies/ml (Table 1).
The functional titers of rAAV2/7—CaMKIIα 0.4 and rAAV2/
7—CaMKIIα 1.3 were determined as described earlier.46 Briefly,
75.000 HEK-293T cells were incubated with a serial dilution of
the respective rAAV vectors for 72 h. Following transduction,
cells were washed, trypsinized, and the cell pellet was washed
three more times with PBS. About 100 ng of genomic DNA
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was used for the determination of the rAAV genomic copies using
a real-time PCR, as described earlier.33 Each dilution of the viral
vectors was used three times and this experiment was done in two
different assays.
A univariate general linear model test was performed with
SPSS v16.0 for Windows to compare the effects of the dilution
and promoter sequence (CaMKIIα 0.4 or CaMKIIα 1.3) on the
functional titers, with the assay number as a cofactor. Bonferroni
posthoc tests were performed to determine specific differences
between the groups. The significance level was set to p < 0.05
for all statistical analyses.
2.3 Vector Injections
For the cortical injections of the vector, monkeys were
first sedated with Domitor and Ketalar (50 mg∕kg, intramus-
cular, Pfizer) and anesthetized with isoflurane (1.2%).
Postoperatively, the animals were treated with analgesics
(Contramal, i.m.) and antibiotics (Kefzol, i.m). Five separate
series of injections were performed, two in M10 (separated
by 7 weeks) and three in M37 (separated by 6 and 3 weeks,
respectively; Table 1). The time between the last series of injec-
tions and the perfusion was 4 weeks for both subjects. Four
series of injections targeted area V1 and one series prefrontal
cortex (area 46). Craniotomies were performed above area
V1 (M10 and M37) and above frontal cortex (only in M37).
After incising and partially retracting the dura mater, viral vec-
tors were injected using a Nanoject II Auto-Nanoliter Injector
(Drummond Scientific Company) attached to a custom-built
micromanipulator with three translational degrees of freedom
(XYZ-manipulator). Next, the vector was loaded into pulled
glass micropipettes (outer diameter of 50 μm). At each location,
a total volume of 920 nL was injected at 10 equally distributed
positions between the gray-white matter boundary and the pial
surface (total distance of 1.8 mm) with a series of four injections
of 23 nL each at a single position every 10 s and applying
an interval of 2 min between consecutive vertical positions
[Fig. 1(a)].
Table 1 Overview of injected viral vectors in M10 and M37. The short solid lines separate the different injection sessions. Identical serotype/
promoter injections in M10 and M37 are labelled in bold.
Serotype Promoter FP Titer (E12) Survival time Region Hemisphere
M10
A rAAV2/7 hCMV EGFP 1.9 29 d V1 R
B rAAV2/7 MmCaMKIIα0.4 EGFP 2.6 29 d V1 R
C rAAV2/5 hCMV EGFP 0.4 29 d V1 R
D rAAV2/8 hCMV EGFP 2.6 78 d V1 L
E rAAV2/9 hCMV EGFP 3.2 78 d V1 L
F rAAV2/7 MmCaMKIIα1.3 EGFP 2.6 78 d V1 L
M37
G rAAV2/1 hCMV EGFP 1.1 93 d DLPC R
H rAAV2/8 hCMV EGFP 1.9 93 d DLPC R
I rAAV2/9 hCMV EGFP 1.2 93 d DLPC R
J rAAV2/7 MmCaMKIIα0.4 EGFP 2.6 93 d DLPC R
K rAAV2/1 MmCaMKIIα0.4 EGFP 1.0 52 d V1 L
L rAAV2/5 MmCaMKIIα0.4 mCherry 4.8 52 d V1 L
M rAAV2/8 MmCaMKIIα0.4 EGFP 2.8 52 d V1 L
N rAAV2/9 MmCaMKIIα0.4 mCherry 3.1 52 d V1 L
O rAAV2/7 MmCaMKIIα1.3 EGFP 3.0 52 d V1 L
P rAAV2/7 hCMV EGFP 1.5 29 d V1 R
Q rAAV2/7 hCMV(en)hSyn mCherry 1.3 29 d V1 R
R rAAV2/7 MmCaMKIIα0.4 EGFP 3.1 29 d V1 R
S rAAV2/7 MmCaMKIIα1.3 mCherry 2.1 29 d V1 R
Note: FP, fluorescent protein; CMV, cytomegalovirus promoter; CaMKIIα, α-calcium/calmodulin-dependent protein kinase II promoter; enhSyn1,
CMV enhanced human Synapsin-1 promoter; promoter size sequence: 0.4 and 1.3 kb; rAAV, recombinant adeno-associated viral vector; EGFP,
enhanced green fluorescent protein; d, days; DLPC, dorsolateral prefrontal cortex; V1, primary visual cortex.
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To match the vector to its corresponding position, a photo
was taken and distances to main anatomical landmarks (e.g.,
sulci) were measured at each injection site [see Fig. 1(b) for
schematic overview of the injection sites relative to sulci and
the border of the respective craniotomies]. Once the viral vector
injections were completed at a particular site, the dura mater was
sutured, the original bone was used to cover the craniotomy, and
the skin was closed over the bone flap.
2.4 Perfusion
Four weeks after the final injection series, both monkeys were
deeply anesthetized (ketalar, 50 mg∕kg, intramuscular, Pfizer)
and euthanized using an overdose of pentobarbital (intravenous,
30 mg∕kg, Sigma). The animal was then transcardially perfused
using isotonic saline [9% NaCl in 0.1 M phosphate buffer, pH
7.4 (PB)], followed by 3.5% paraformaldehyde in PB solution
and finally with 5% glycerol in PB for cryoprotection.
Subsequently, the brain was removed from the skull, cut in
six to eight pieces and stored for 3 days in 10% and 3 days
in 20% glycerol–PB solution. Tissue pieces were quickly frozen
in 2-methylbutane (Merck) at −30 to −40°C, stored at −80°C,
and sectioned with a cryostat at −30°C (50-μm-thick coronal
sections). The sections were stored as free-floating sections
in 0.01% sodium azide containing PBS buffer (0.15 M, pH
7.4) at 4°C until further processing.
2.5 Histology
Since the pipette tracks caused by the injections were not visible
in unstained sections, a series of cryosections (every 200 μm)
were mounted onto glass plates. Cresyl violet and immunohisto-
chemical fluorescent protein (FP) staining were then performed
on two different series. Based upon the FP-staining, the injection
sites could be determined as the sections with the highest pro-
portion of FP-labeled cells across all layers. Parvalbumin (PV)
and NeuN stainings were additionally performed on a series of
adjacent sections to calculate the percentage of FP+ cells com-
pared to the total number of neurons (NeuN) and to ascertain
cell-type specificity (PV).
2.5.1 Cresyl violet staining
Free-floating sections (50 μm) were mounted onto poly-L-
lysine-coated (Sigma-Aldrich) glass slides and kept at 37°C
for 1 day (Heraeus, type B5050). Cresyl violet staining was
then performed according to standard methods to delineate
areal borders and cortical layers delineation, as previously
described.47,48
2.5.2 Immunohistochemistry
Table 2 summarizes all details concerning antibodies, dilutions,
and buffers used in immunohistochemistry. All free-floating
sections (50 μm) were washed twice in 1× tris-buffered saline
Fig. 1 Injection procedure across cortical layers. (a) Schematic representation of injection procedure. In
total, 920 nL of each vector was injected across 10 equidistant positions in depth (indicated with purple
dots), with a spacing of 0.18 mm perpendicular to the cortex. (b) Cortical locations of all injection sites
within each craniotomy with an indication of the neighboring sulci that were visible during surgery (left and
right V1 for M10, left and right V1 and right 46a for M37). Abbreviations: A, anterior; AS, arcuate sulcus;
Ext. CS, external calcarine sulcus; L, lateral; LUS, lunate sulcus; M, medial; P, posterior; PS, principale
sulcus; wm, white matter.
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or 1× PBS 0.1% TRITONX-100 (for NeuN) (10 min) and then
pretreated for 45 min with preimmune goat serum [(PIG);
1:5 dilution]. For NeuN staining, an additional pretreatment for
20 min in a methanol 0.3% peroxide solution preceded the
PIG incubation step. After overnight, incubation at 4°C with
primary antibody (Table 2) sections was rinsed in wash buffer.
The tissue was then incubated at room temperature (RT) for
2 h with appropriate secondary antibodies (Table 2). For biotiny-
lated secondary antibodies, slices were additionally washed
(3 × 10 min) and incubated with streptavidin-Cy5 at RT for
2 h (1:500, invitrogen). Following 3 × 10 min washing steps
in wash buffer, the sections were rinsed quickly in aqua destillata
and sections were incubated for 30 min in 4′,6-diamidino-2-phe-
nylindole (2 μl∕100 ml 0.1 M PBS). Finally, the floating slices
were mounted onto gelatin-bloom coated slides (0.05% gelatin
bloom solution, type 2, sigma) and cover-slipped with mowiol
mounting medium for examination by fluorescence microscopy.
2.6 Image Acquisition
All (immuno-)histochemically stained sections were imaged
(10×, 20×, and 40× dry lenses) with a Zeiss Axio-Imager micro-
scope equipped with Zeiss CCD Axiocam black and white and
color cameras (MRc3 and MRc5, respectively). Fluorescent pho-
tographs for semiquantification were additionally acquired with
an Olympus Fluoview FV1000 inverted confocal microscope
(4×, 10×, and 20× objectives) and using the Olympus Fluoview
acquisition software 3.0a. After defining the region of interest, the
software divided this region into four to six sections and a z-stack
(to cover the 50-μm-thick slice) was acquired.
2.7 Proportion of Transduced Neurons
To determine the fraction of all neurons and inhibitory-specific
neurons transduced for each vector, confocal images of the
NeuN stainings and PV stainings were taken. To approximately
define the proportion of colocalizing cells, a semiquantitative
analysis (i.e., manual quantification in one section) was per-
formed. Therefore, images were first cropped to the preferred
size. Layers were then defined based on NeuN stainings and
compared to neighboring CV-stained slices. Afterward, the
overlap with fluorescently labeled neurons was manually scored
and quantified across the different cortical layers for each image,
as described in Diester et al.,35 using ImageJ (image processing
and analysis in Java, National Institute of Health).
When a percentage of transduced neurons is mentioned in the
results, these numbers were obtained from sections adjacent to
the injection site. The percentage was calculated as the number
of colocalized FP+ and NeuN+ cells divided by the total number
of NeuN+ cells multiplied by 100. The numbers representing the
spread are based on the maximal distance from the injection site
at which FP+ cells were found across the cortical surface. The
anterior–posterior (A-P) axis is always mentioned first followed
by the spread along the lateral–medial (L-M) axis.
3 Results
We injected a series of rAAV vectors into two cortical brain
regions of both hemispheres in two monkeys (M10 and
M37) to determine their transduction efficiency and apparent
distribution pattern, as evaluated by reporter gene expression
(Fig. 1). In M10, serotypes rAAV2/5, 2/7, 2/8 and 2/9 were
Table 2 Overview of primary and secondary antibodies used in immunohistochemical staining.
Single Staining
FP Primair antibody Buffer (1: X) Secundair antibody (in TNB) (1: X)
G Mm anti-parvalbumin (Swant) TNB 60000 Biotinylated GAM (polyclonal; invitrogen) 500
G Rb anti-EGFP (Lab. NB-GT) TNB 10000 GAR IgG, AF594 (PC, ab150088; Abcam) 250
G Mm anti-parvalbumin (Swant) TNB 60000 GAM IgG, AF594 (PC, ab150120, Abcam) 250
R Rb anti-RFP (ab 600-401-379; Rockland) TNB 5000 GAR IgG, AF488 (PC, ab150085, Abcam) 250
Double Staining
FP Primair antibody Buffer (1: X) Secundair antibody (in TNB) (1: X)
G Rb anti-EGFP (Lab. NB-GT) PBS* 10000 GAR IgG, AF488 (PC, ab150085, Abcam) 250
G Mm anti-NeuN (MAB377, Merck) PBS* 200 GAM IgG, AF594 (PC, ab150120, Abcam) 250
G Rb anti-EGFP (Lab. NB-GT) PBS* 10000 GAR IgG, AF488 (PC, ab150085, Abcam) 250
G Mm anti-NeuN (MAB377, Merck) PBS* 200 GAM IgG, AF594 (PC, ab150120, Abcam) 250
R Rb anti-RFP (ab 600-401-379; Rockland) PBS* 5000 GAR IgG, AF594 (PC, ab150088, Abcam) 250
R Mm anti-NeuN (MAB377, Merck) PBS* 200 GAM IgG, AF488 (PC, ab150117, Abcam) 250
Note: Mm, mouse; PBS*, phosphate-buffered saline 0.1%Triton-X100 10%PIG; PC, Polyclonal; R, mCherry-RFP; Rb, Rabbit;
Ab, Abcam, Cambridge, United Kingdom; G, EGFP; Lab. NB-GT, Laboratory of Neurobiology and Gene Therapy, KU Leuven, Belgium; Merck,
Merck Milipore, Darmstadt, Germany; invitroge, (Invitrogen Corporation, Carlsbad, California; Rb, Rabbit; RL, Rockland Immunochemicals Inc.,
Gilbertsville, Pennsylvania; Swant, Swant swiss antibodies, Switzerland; TNB, tris-NaCl-blocking buffer, 1× TBS, 0.5% blocking buffer.
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injected into left and right area V1. FP-expression was driven by
i) a constitutive CMV promoter (rAAV2/5, 2/7, 2/8 and
2/9), ii) a long, or iii) short version of the excitatory cell type-
specific CaMKIIα promoter (rAAV2/7). The long version of
the CaMKIIα promoter (1.3 kb; CaMKIIα1.3) has been used
previously and was found to transduce excitatory cells in several
species including mouse, rat and monkey.43,49–51 Additionally,
a shorter CaMKIIα promoter (0.4 kb; CaMKIIα0.4)52 was con-
structed to facilitate packaging of larger genes (e.g., opsins) in
future experiments.
In the second monkey (M37), three injection sessions were
carried out. In the first session, the rAAV2/1, 2/8 and 2/9 CMV
Fig. 2 Transduction patterns in V1 after rAAV2/1-CaMKIIα0.4 injection. (a) Nissl stained section used to
establish the borders of the cortical layers. (b) FP+ cells on an adjacent section after injection of the
rAAV2/1-CaMKIIα0.4 vector in M37. (c)–(e) Enlarged views of the sectors indicated in b (c: top, d: middle,
and e: bottom frame). Scale bar in panels a and b ¼ 200 μm. Scale bar in panels c to e ¼ 50 μm.
Fig. 3 Transduction patterns in V1 for rAAV2/5-CaMKIIα0.4. (a) and (b) Adjacent sections after injection
of the rAAV2/5-CaMKIIα0.4 construct in V1 of M37. The left panel indicates the laminar pattern in V1.
(b) FP+ expression profile across all layers. Expression of mCherry is detected mostly in the superficial
and deeper layers (panels c and e). Weak FP+ expression was found in layer III and IV (panel d). Scale
bar in panels a and b ¼ 200 μm. Scale bar in panels c to e ¼ 50 μm.
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vectors and a rAAV2/7-CaMKIIα0.4 vector were injected into
dorsolateral prefrontal cortex to confirm results obtained in the
first monkey. In a second session, performed 6 weeks later, dif-
ferent serotypes (rAAV2/1, 2/5, 2/7, 2/8 and 2/9) under control
of the same promoter (CaMKIIα0.4) were injected into left area
V1 to compare transduction efficiencies of these serotypes with
the results obtained after injections in rodent V1. In the final
series of injections (3 weeks later), vectors with the same sero-
type (rAAV2/7), but with different promoters (CMV, enhSyn1,
CaMKIIα0.4 and CaMKIIα1.3), were injected to reveal the
effect of the promoter on the transgene expression. Identical
injections in V1 and prefrontal cortex (area 46) were designed
to compare transduction patterns across two entirely different
neocortical areas.
Following a description of the FP expression at the injection
sites, we will give an overview of retro-and anterograde expres-
sion patterns in the dorsal lateral geniculate nucleus (dLGN).
Finally we will provide a semi-quantitative overview of the
cortical FP expression patterns in a final summary figure.
3.1 Recombinant Adeno-Associated Viral Vector
Serotype-Dependent Laminar Transduction
Patterns
Figures 2 through 6 illustrate differences in transduction effi-
ciencies and laminar FP expression patterns in striate cortex fol-
lowing injection of different rAAV serotypes (2/1; 2/5; 2/7; 2/8;
and 2/9) under control of the CaMKIIα0.4 promoter. Vectors
used for Figs. 2, 3, 5, and 6 were injected in M37, while trans-
duction of rAAV2/7-CaMKIIα0.4 was also tested in a second
monkey (M37 and M10; Fig. 4).
The rAAV2/1-CaMKIIα0.4 vector resulted in a relatively
focal expression pattern covering approximately 1.2 × 1.0 mm2
of cortex along the A-P and L-M axes. FP+ cells were observed
in almost every layer of V1 near the injection site (Fig. 2).
Transduction and EGFP expression after rAAV2/1-CaMK0.4
injection was stronger for infragranular and superficial cortical
layers than in granular layers (Fig. 2). In particular, layers IVcα
and IVcβ showed the weakest reporter activity in neurons.
In addition to expression in neurons, positive glial cells were
observed in the superficial layers [Fig. 2(c)].
Injection of rAAV2/5-CaMKIIα0.4 also yielded FP+ cells
near the injection site, although a clearly less homogeneous
expression pattern was observed across layers than with the
rAAV2/1 vector [Figs. 2(b) and 3(b)]. Compared to rAAV2/1,
neurons transduced by the rAAV2/5-CaMKIIα0.4 vector were
found at substantially greater distances from the injection site
along the A-P and L-M axes (∼7.8 × 5.0 mm). The greater
spread was observed mainly in the deepest layers. Transduction
efficiency was especially high in layers I (fibers), VI [fibers
and cells; Fig. 3(e)] and at the top of layers II/III [mostly
cells; Fig. 3(c)] and relatively low in the lower part of layers
II/II, layers IVcα and IVcβ and the upper part of layer V.
EGFP expression was also less pronounced in layers IVa and
IVb (Fig. 3).
Injection of V1 with the rAAV2/7-CaMKIIα0.4 construct
yielded FP+ cells mainly in the superficial and deeper layers
in both monkeys (Fig. 4). The largest fraction of transduced
cells was observed in layers II/III (Fig. 4, panels c and h), fol-
lowed by layer Vand layer VI (Fig. 4, panels e and j). Although
neuropil was FP+ in layers IVb, IVc, and IVc, these layers
contained relatively few FP+ cells. Hence, this vector was
less than optimal for NeuN transduction in the granular layers.
The rAAV2/7-CaMKIIα0.4 vector transduced cells (mostly neu-
rons) at greater distances from the injection site compared to
rAAV2/1, but the spread parallel to the cortical surface was
more restricted compared to the rAAV2/5 vector [layer VI:
ð2.9 1.9Þ × ð2.8 0.4Þ mm; (mean SD) across subjects].
Injection of rAAV2/8-CaMKIIα0.4 resulted in FP+ cells
through all cortical layers, with the highest fraction in the deeper
layers (Fig. 5). The spread of FP-labeled cells was rather limited
along the A-P and L-M axes with a slightly wider spread in the
deepest layers (1.8 × 2.0 mm). In addition, many FP-positive
glial cells were detected, most notably in the granular layers,
making this serotype less specific for NeuN transduction
[Fig. 5(c)].
Injection of serotype rAAV2/9 with a reporter under control
of the CaMKIIα0.4 promoter transduced relatively few cells in
the supragranular and granular layers in contrast to infragranular
layer VI (Fig. 6). The fraction of FP+ neurons was similar to the
total number of transduced cells making it better for NeuN
expression in comparison to rAAV2/8 but less optimal than
rAAV2/7. The spreading of FP-expression induced by this
vector is again rather limited (layer VI: 1.2 × 2.0 mm2).
Fig. 4 Transduction patterns in V1 for rAAV2/7-CaMKIIα0.4.
Transduction pattern after injection of the rAAV-CaMKIIα0.4 construct
in V1 of M10 (top) and M37 (bottom). (a) and (f) show cresyl violet
stained sections, middle (b and g) and right panels (c, d, e, g, h, I,
j) show the EGFP expression in adjacent sections at lowmagnification
and high magnification, respectively. Scale bars in left and middle
panels ¼ 200 μm. Scale bars for right column ¼ 50 μm.
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Thus, when the CaMKIIα0.4 promoter is injected into mon-
key striate cortex, the number of cells that express the transgene
in V1, the spread from the injection site, and the expression in
the various cortical layers depend on the serotype.
3.2 Promoter-Dependent Transgene Expression
after rAAV2/7 Transduction
We next compared transgene expression driven by different
promoters while using the same rAAV serotype. We chose
the rAAV2/7 serotype because the previous test yielded a high
ratio of transduced neurons in both supra- and infragranular
layers and also because results of a previous mouse study
using exactly the same constructs as the present study showed
high transduction efficiency in area V1.23 We injected a series
of rAAV2/7 vector constructs containing the CMV, enhSyn1,
CaMKIIα0.4, or CaMKIIα1.3 promoters. These rAAV2/7 con-
structs were injected into V1 of both animals, with the exception
of enhSyn1 (M37 only).
Fig. 5 Transduction patterns in V1 for rAAV2/8-CaMKIIα0.4. (a) Nissl-stained section of V1 from M37.
(b) FP+ cells in an adjacent section after injection of the rAAV2/8-CaMKIIα0.4 vector in V1. Right panels
(c, d, e), enlargements showing FP+ cells from the insets shown in b. Scale bars in left and middle
panels ¼ 200 μm. Scale bars for right column ¼ 50 μm.
Fig. 6 Transduction patterns in V1 for rAAV2/9-CaMKIIα0.4. (a) Cresyl violet staining of V1 from M37.
(b) EGFP+ cells from an adjacent section. (c)–(e) shows higher magnifications of the insets in panel (b).
Scale bars in left and middle panels ¼ 200 μm. Scale bars for right column ¼ 50 μm.
Neurophotonics 031209-8 Jul–Sep 2015 • Vol. 2(3)
Gerits et al.: Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vector. . .
The transduction pattern induced by the rAAV2/7-
CaMKIIα0.4 vector has already been described above (Fig. 4).
Surprisingly, when the longer version of the CaMKIIα promoter
was used (rAAV2/7-CaMKIIα1.3), a remarkably different
laminar expression pattern emerged (Fig. 7). In addition to
transducing cells in layers II/III, V, and VI, as with the
rAAV2/7-CaMKIIα0.4 vector, the rAAV2/7-CaMKIIα1.3 vec-
tor also strongly transduced cells in layers IVa and IVb
[Figs. 7(d) and 7(i)]. Furthermore, in contrast to the short
CaMKIIα0.4 promoter, hardly any FP+ neurons were found
in layer IVcβ (compare Figs. 4 and 7). Overall, the long
CaMKIIα promoter resulted in a more efficient transgene
expression and labeled cells at greater distances from the
injection site than the short promoter (A-P × L-M; layer VI:
½7.7 3.2 × ½4.8 2.5 versus ½2.9 1.9 × ½2.8 0.4 mm;
mean SD of both monkeys for the long versus short
CaMKIIα promoter).
The rAAV2/7-CMV vector used in the present study dis-
played reasonable reporter levels throughout primary visual cor-
tex (Fig. 8). Moreover, EGFP expression was lowest in layers II/
III [Fig. 8(c)] and maximal in the deeper layers [Fig. 8(e)]. The
majority of the EGFP+ cells after rAAV2/7-CMV injection,
however, were non-neural [Fig. 8(b) inset]. In M10, only a
few PF+ cells and fibers were detected and no transduced
neurons could be found; hence, this monkey was not used for
illustrating this vector.
In the second monkey, we injected a vector for which the
enhancer region of a CMV promoter53 was fused with the
human Synapsin promoter35,54,55 (i.e., enhSyn1). This promoter
in a rAAV2/7 vector yielded a relatively homogeneous transgene
expression across all cortical layers (Fig. 9) and resulted in FP+
cells at larger distances from the injection site compared to the
rAAV2/7-CMV vector. Furthermore, a semiquantitative analysis
revealed that the fraction of FP+, non-neural cells was very low
(<2%) compared to the CMV promoter (>90%), which renders
the former vector more suited for transduction in V1.
3.3 Cell Specificity of a Long and Short Version of
the CaMKIIα Promoter
Viral vectors are the most efficient means with which to transfer
genetic material into the central nervous system. Specific
expression of a reporter or a therapeutic protein is conditional
on the combination of serotype and promoter.17,56 Here, we
tested whether the CaMKIIα promoter is specific for excitatory
cells, as is generally assumed.42,43 Therefore, we performed dou-
ble stainings between FP+ cells and the inhibitory cell marker
(PV), which is expressed by 75% of the inhibitory cells in pri-
mate striate cortex.57 We calculated the number of FP+ neurons
that were also PV+ after injection of two rAAV2/7 vectors
driven by either a short or a long CaMKIIα promoter.
No overlap was found between FP+ and PV+ cells after
injecting the rAAV2/7-CaMKIIα0.4 vector [Figs. 10(a) and
10(c)]. Surprisingly, however, injection of the rAAV2/7-
CaMKIIα1.3 vector yielded double-stained cells in both mon-
keys, indicating that at least a fraction of the cells transduced
with this CaMKIIα promoter is inhibitory in nature [Figs. 10(b)
and 10(d)]. We next calculated the fraction of neurons that are
both PV+ and FP+. As shown in Fig. 10(e) (pooled data, M10
and M37), the short promoter revealed no overlap between FP+
and PV+ neurons. Injections with the CaMKIIα1.3 viral vector
construct resulted in 3.2 0.1% double-stained FP+ PV+ neu-
rons across all the layers in V1. When considering the fraction of
PV+ neurons that are also FP+ [Fig. 10(e), solid purple curve]
for each layer, we found that up to 29% of the FP+ cells in layer
IVcα are PV+, 17% in IVcβ, and 13% in layer V. For the other
layers, the degree of overlap was below 2%. Since the highest
proportion of PV+ cells is found in layer IVc,57 this might
explain why we found the highest percentage of FP+PV+
neurons in this layer. Hence, the CaMKIIα0.4 promoter is
more specific for excitatory cells than the longer CaMKIIα1.3
promoter.
Although genomic titers were comparable between the two
vectors, differences between CaMKIIα0.4 and CaMKIIα1.3 in
their specificities for excitatory cells could be due to different
functional titers. For this reason, the functional titers of
rAAV2/7-CaMKIIα0.4 and rAAV2/7-CaMKIIα1.3 were deter-
mined by dilution assays (Fig. 11) (see also Ref. 23). The dilu-
tion of the viral vector solution influenced the measured titers
(p < 0.001) but not the genomic titer of the vector construct
(p ¼ 0.152). Thus, because the same dilutions were injected
for these vectors, differences in functional titers cannot explain
the differential specificity for excitatory neurons in these two
promoter sequences.
Fig. 7 Transduction patterns in V1 for rAAV2/7-CaMKIIα1.3. (a) and
(f) Nissl-stained sections of V1 are shown for M10 (top) and
M37 (bottom). (b) and (g) Transduction pattern of the rAAV2/7-
CaMKIIα1.3 vector on adjacent sections. (c), (d), (e), (h, (i), (j) Higher
magnified sections as indicated in the insets are shown on the right.
Scale bars in left and middle panels ¼ 200 μm. Scale bars for
right column ¼ 50 μm.
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3.4 Projections to the Dorsal Lateral Geniculate
Nucleus
One generally assumes that rAAV viral vectors do not transfer
trans-synaptically.58 Thus, FP+ cell bodies found at greater
distances from the injection site are labeled retrogradely via
transduced fibers entering the injection site. The retrograde
capacity of rAAV2 vectors was previously shown by Towne
et al.59 and Zhang et al.60 Since the dLGN is bidirectionally con-
nected with area V1, we hypothesized that this thalamic nucleus
Fig. 8 Transduction patterns in V1 for rAAV2/7-CMV. (a) Cresyl violet staining of V1 in M37.
(b) Transduction pattern in an adjacent section after injection of V1 with the rAAV2/7-CMV vector.
The inset in layer VI (panel b) shows limited overlap between FP+ labeled cells (EGFP staining;
green) and neurons (NeuN-staining; magenta). (c)–(e) Higher magnification insets showing that most
FP+ cells were non-neural (i.e., no overlap between NeuN and EGFP staining). Scale bars in left
and middle panels ¼ 200 μm. Scale bars for right column ¼ 50 μm.
Fig. 9 Transgene expression patterns in V1 for rAAV2/7-enhSyn1-mCherry. (a) Nissl-stained section of
V1 of M37. (b) Transduction pattern of the rAAV2/7-enhSyn1 vector for an adjacent section. (c)–(e) High
magnification images of the insets shown in b. Scale bars in left and middle panels ¼ 200 μm. Scale bars
for right column ¼ 50 μm.
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could contain both anterogradely labeled FP+ axon terminals
and retrogradely labeled FP+ cell bodies.
Figure 12 shows coronal sections of the left and right dLGN
with an illustration of the retinotopic maps in panels a and b.61
Panels c and d show, respectively, EGFP+ fibers [Figs. 12(c) and
12(d)] and cells [Fig. 12(d)] in the dLGN of M10. The FP+ pos-
itive fibers in the left dLGN [Fig. 12(c); M10] must originate
from the rAAV2/7-CaMKIIα0.4 vector construct, since the
injection site of this vector corresponded retinotopically with
the location of the FP+ signal in the dLGN and this vector con-
struct transduced the highest proportions of neurons in left V1.
In the right dLGN, we also observed FP-labeled cell bodies,
which are transduced by the rAAV2/7-CaMKIIα1.3 vector
[Fig. 12(d)]. Figures 12(e)–12(h) show FP+ fibers in the left
and right dLGN of M37. Panels e and f reveal EGFP+ fibers,
while the fibers in panels g and h are mCherry+. Since more
than one of the vectors injected in each hemisphere contained
the EGFP or mCherry fluorescent tag, we relied on the detailed
retinotopic location of the respective injection sites in V1 and
transduced fibers in the LGN to define which vector had trans-
duced these fibers. Based on the corresponding retinotopic loca-
tions (eccentricity and polar angle) of the injection sites, we
inferred that the band of fibers in panel e was transduced by
the rAAV2/8-CaMKIIα0.4 vector and those in panel g by the
rAAV2/5-CaMKIIα0.4 vector (approximate eccentricity and
polar angle values of, respectively, 6 to 8 deg and þ15 deg and
2 to 3 deg and þ30 deg). The latter vector also resulted in a
relatively widespread cortical transduction pattern in layer VI
of V1, which can explain the broad signal corresponding to
fibers projecting to the dLGN. For the right dLGN of M37,
we again used retinotopic criteria to determine that the
observed EGFP+ fibers are transduced by the rAAV2/7-
CaMKIIα0.4 vector [eccentricity and polar angle of 4 to
6 deg and þ15 deg; Fig. 12(f)], and the mCherry+ fibers in
the left dLGN by the rAAV2/7-enhSyn1 vector [eccentricity
and polar angle of 4 to 6 deg and −15 deg; Fig. 12(h)]. No
signal corresponding to the injection of rAAV2/1-CaMKIIα0.4,
rAAV2/9-CaMKIIα0.4 and of the CMV driven vectors was
found in the LGN, indicating poor anterograde and retrograde
transport to this thalamic nucleus after injection of these viral
vectors in V1.
Fig. 10 Cell specificities of rAAV2/7-based vectors with long and
short CaMKIIα promoters. (a) and (b) Transduction patterns in V1 of
M10 using the rAAV2/7-CaMKIIα0.4 and rAAV2/7-CaMKIIα1.3 vectors,
respectively. (c) and (d) Transduction patterns using the same vectors
are shown for M37. The left column shows the EGFP signal (green), the
middle column shows the results of PV-staining in magenta. The right
column shows the merged EGFP- and PV stainings (white are double-
stained neurons). The open white arrowheads indicate examples of
nonoverlapping neurons and the filledwhite arrowheads indicate exam-
ples of EGFP+ −PV+ neurons. The inset in panels b and d illustrates
double-stained neurons at higher magnification. (e) The plot illustrating
the fraction of overlapping PV+ and EGFP+ neurons (%) for each cort-
ical layer at the injection site for the CaMKIIα0.4 (dashed purple line
with diamonds), and CaMKIIα1.3 promoters (solid purple line with
squares). The blue plot represents the number of FP+ neurons for
both the short (dashed line with diamonds) and long CaMKIIα (solid
line with squares) promoters to illustrate the low proportion of FP+
neurons in the layers containing a high fraction of FP+ and PV+ over-
lapping cells. Data from both monkeys (M10 and M37) are pooled.
Error bars represent SEM across monkeys (n ¼ 2). Scale bar ¼
20 μm.
Fig. 11 Functional titers of rAAV2/7–CMV and rAAV2/7-CaMKIIα0.4.
The functional titer in GC/ml was determined for three different
dilutions of vector added to HEK-293T cells (black bars ¼ 10 μl,
gray bars ¼ 5 μl, and white bars ¼ 2.5 μl volumes). Only the volume
has an effect on the functional titer. No differences exist between the
serotypes. Water and nontransduced cells were added to the DNA
measurements as controls. ***p < 0.001.
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Thus, injection of rAAV2/7-CaMKIIα0.4, rAAV2/7-
CaMKIIα1.3, rAAV2/7-enhSyn1, rAAV2/5-CaMKIIα0.4, and
rAAV2/8-CaMKIIα0.4 in V1 resulted in anterogradely labeled
FP+ axon terminals in the LGN, whereas retrogradely labeled
FP+ cell bodies were found only after rAAV2/7-CaMKIIα1.3
vector injections.
3.5 Comparison of rAAV2/7-Mediated
Transduction Patterns in V1 and
Dorsolateral Prefrontal Cortex
First, to determine whether the transduction efficiencies and
expression patterns described in the present study are specific
for V1 or are similar in different cortical areas, one vector
(rAAV2/7-CaMKIIα0.4) was injected in area V1 and in the
dorsolateral prefrontal cortex (area 46) of one monkey (M37).
Transduction was more homogeneous across all layers of
area 46 compared to V1 (Fig. 13), but the area of lateromedial
spread in layer VI was half of that in area 46 (2.4 mm versus
5.0 mm). The anteroposterior spread, however, was equal in the
two areas (3.0 mm).
3.6 Comparison of Cytomegalovirus-Mediated
Transduction Patterns in V1 and
Dorsolateral Prefrontal Cortex
Finally, to confirm that the absence of FP+ neurons after injec-
tion of the CMV-promoter-driven constructs is not restricted to
V1, the same vectors were also injected into area 46. All injected
CMV- constructs (rAAV2/1-CMV, rAAV2/8-CMV and rAAV2/
9-CMV) failed to show transgene expression in prefrontal cort-
ical neurons in macaque neocortex.
4 Discussion
We injected a series of rAAV serotypes (rAAV2/1; 2/5; 2/7;
2/8; 2/9) controlled by multiple promoters (CaMKIIα0.4,
CaMKIIα1.3, CMV, and enhSyn1) into primary visual and
dorsolateral prefrontal cortex of rhesus monkey and studied
the transduction efficiency, spread and laminar expression
based on cellular EGFP or mCherry fluorescent reporter gene
expression.
4.1 Transduction Efficiencies are Serotype
Dependent
Primate cortical neurons were successfully transduced with
rAAV2/1, rAAV2/5, rAAV2/7, rAAV2/8, and rAAV2/9.
Earlier reports by Markakis39 and Dodiya41 showed variations
in the number of macaque neurons transduced depending on
the serotype used. In these previous reports, rAAV2/1 and
rAAV2/5 proved the most efficient vectors. They transduced
a large number of cells in the basal ganglia, striatum, and sub-
stantia nigra (SN) of the primate brain. Other studies with injec-
tions in the SN of rats reported higher transduced brain volumes
using rAAV2/7, rAAV2/9, and rAAV2/1 than with rAAV2/8 and
rAAV2/5, indicating species-dependent transduction efficien-
cies of the viral vectors.30,33,62 In our study, the rAAV2/1-
CaMKIIα0.4 showed efficient transduction at the injection
site but the transgene expression pattern was limited to about
1.2 × 1.0 mm2. This corroborates a recent report by Jazayeri
et al.54 in which the rAAV2/1 vector, including the hSyn pro-
moter, was injected into this same cortical area. These authors
reported a small band of ChR2-positive cells at the injection site,
with only a few transduced neurons 1 mm away. Furthermore,
despite uniform injection throughout the cortical depth, they
also found layer-specific expression of the gene-of-interest, pos-
sibly due to the characteristic tropism of the rAAV2/1 vector.54
Vector rAAV2/5 has been reported to disperse further from
the injection site in both mice and primates.23,32,35,63 Also in the
present study, rAAV2/5-CaMKIIα0.4 injections resulted in the
Fig. 12 Retinotopic-specific antero-and retrograde transduction in
dLGN after injection of rAAV vectors in V1. (a) and (b) Retinotopic
map of a coronal section of the left and right LGN as determined
by Malpeli and Baker61 (reprinted with permission). (c) and
(d) Retinotopic-specific, anterogradely labeled fibers and retrogradely
labeled cells in the LGN after injection of rAAV2/7-CaMKIIα0.4 and
rAAV2/7-CaMKIIα1.3 in V1 of M10, respectively. In M37, (e) and
(f) EGFP-positive fibers and (g) and (h) mCherry-positive fibers were
found. The FP+ fibers in panels (e) and (g) are induced by V1 injec-
tions with the rAAV2/8-CaMKIIα0.4 and rAAV2/5-CaMKIIα0.4 vectors,
respectively. In panels (f) and (h) (right LGN), the EGFP+ fibers are
induced by rAAV2/7-CaMKIIα0.4 and rAAV2/7-enhSyn1 injections in
V1, respectively. Scale bar ¼ 500 μm.
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most widespread (7.8 × 5.0 mm2) transduction across layers II/
III, V, and VI. Other serotypes, such as rAAV2/7, showed a
spread of ð2.9 1.9Þ × ð2.8 0.4Þ mm (i.e., mean of both
monkeys ± SD), while rAAV2/8 and rAAV2/9 showed smaller
spreads [ð1.8 × 2.0Þ and ð1.2 × 2.0Þ mm, respectively]. We
summarized the results of our semiquantitative comparisons
in Fig. 14 and ranked the AAV serotypes containing the
CaMKIIα0.4-promoter by transduction efficiency based on
the cortical spread: rAAV2/5>>rAAV2/7>rAAV2/8>rAAV2/
9>>rAAV2/1. This ranking differs only for rAAV2/8 and
rAAV2/9 from that reported for mouse visual cortex using
exactly the same vector batches (rAAV2/5 >> 2/7 ≥ 2/9 ≥
2/8 >> 2/1),23 but more substantially with regard to primate
SN, striatum, and basal ganglia (rAAV2/5 ≥ rAAV2/1 >
rAAV2/839,41).
Additionally, for the percentages of transduced neurons at
injection sites, we could rank the rAAV serotypes as follows:
rAAV2/1>rAAV2/5>rAAV2/7=rAAV2/9>rAAV2/8. When aim-
ing for an rAAV serotype with a high percentage of transduced
cells at the injection site and a widely spread transduction, the
ranking is as follows: rAAV2/5 > rAAV2/7 > rAAV2/1 >
rAAV2/8 = rAAV2/9 (see Fig. 14).
4.2 Promoter-Dependent Transgene Expression
Levels
The serotype of the vector determines which cells can be trans-
duced by the viral particles. Furthermore, the promoter should
also be active in expressing the reporter protein in these cells.
Thus, the combination of serotype and promoter determines the
transduction pattern. Despite the widespread use of the CMV
promoter in rodents,32,33,64–66 we were unable to transduce neu-
rons efficiently with rAAV carrying the CMV promoter in pri-
mate cortical neurons, in both visual and prefrontal cortices.
Recently, Watakabe et al.18 reported neural toxicity caused by
the CMV promoter when survival time after injections exceeded
21 days (in our case between 29 and 93 days). In line with this
study, we also found more than 90% of the transgene expression
driven by rAAV2/7 CMV in glial cells instead of neurons.
In contrast to results with the CMV promoter, the human syn-
apsin-1 promoter11,35,55 combined with the enhancer elements of
the CMV promoter (enhSyn1) yielded a homogenous expres-
sion pattern across all cortical layers. The hSyn1 promoter
sequence efficiently recruits TFs in monkey neurons based
on the high expression levels driven by the enhSyn1 promoter
in these cells. In rodents, NeuN TFs have been shown to have
a high affinity for the hSyn1 promoter.63,64 Adding the CMV
enhancer sequence (enhSyn1) additionally improves the neu-
ron-specific transcriptional activity of the hSyn1 promoter, in
line with previous reports.67,68
Another surprising finding was the different transduction
patterns induced by two highly similar viral vector constructs
consisting of different lengths (364 bp and 1291 bp) of the
CaMKIIα promoter. We found that in V1, the short 0.4 kb
CaMKIIα-promoter transduces neurons in all layers, with the
least efficiency in layers IVb and IVcα. The long version
CaMKIIα-promoter selectively transduced cells in all cortical
layers, however, few neurons in layer IVcα and IVcβ. Thus,
the main distinction between the transduction efficiencies of
these two versions of the CaMKIIα promoters can be found
in the granular layers. The laminar expression of CaMKIIα
mRNA in primate V1 has been well described 69–71 but fails
to explain the differences we observed between the transduction
patterns of the two versions of the CaMKIIα promoters used in
this study. For instance, layer IVb is almost void of CaMKIIα
mRNA signal,69,71 which fits with the low number of transduced
cells in layer IVb using the CaMKIIα0.4 promoter but not with
the reasonably high transduction levels using the CaMKIIα1.3
promoter. Based on the lack of expression in specific layers
using the CaMKIIα1.3 promoter, we speculate that factors
that can inhibit transcription, such as specific miRNAs, may
bind to the extra fragments in the longer version of the
Fig. 13 Comparison of transduction patterns in V1 and prefrontal cortex. (a) and (b) Transduction
pattern of rAAV2/7-CaMKIIα0.4 in the dorsolateral prefrontal cortex and in the primary visual cortex.
The left images show the FP+ cells. The figures on the right are the corresponding photographs of
Nissl staining. Scale bar is 200 μm.
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CaMKIIα promoter. Conversely, higher expression levels
induced by the CaMKIIα0.4 promoter may result from the
loss of this inhibitory regulation. Irrespective of the reasons
for transductional disparities between the short and long
CaMKIIα promoters, the former is more specific for excitatory
cells when used in combination with AAV.
Other than the specific laminar expression patterns of the two
CaMKIIα-promoters, differences in cell specificity were also
observed. The rAAV2/7-CaMKIIα0.4 vector resulted in trans-
gene expression exclusively in excitatory neurons while, some-
what surprisingly, rAAV2/7-CaMKIIα1.3 also drove expression
in a small proportion of V1 PV-positive cells. Despite the rel-
atively small fraction of PV+FP+ neurons across the cortical
depth as a whole, in some layers (e.g., IVcα) almost one third
of the transduced neurons were inhibitory in nature. The latter
results are contrary to findings in most nonhuman primate42,43
and rodent studies,49,51,52,72 where selective expression in excita-
tory cells was reported when the CaMKIIα promoter is used.
A study by Nathanson et al.46 already showed the lack of
specificity of the CaMKIIα promoter when used in an AAV vec-
tor, and recent results in mice have confirmed this finding.50
Furthermore, these authors reported that the specificity of len-
tiviral vectors with the CaMKIIα promoter is largely due to the
tropism of the lentivirus, in which the CaMKIIα can provide
additional selectivity. Also in line with our results, the fugu-
derived CaMKIIα promoter in an rAAV2/1 vector drives expres-
sion in a small fraction of inhibitory neurons.73 In that study,
the percentage of excitatory positive-labeled cells was much
higher, exactly as in the present study.
4.3 Retrogradely Transduced Cells
Previous studies showed that rAAVs can transduce cells retro-
gradely in nonhuman primates39,58,74,75 and rodents.30,32,76–79 We
confirmed this observation by showing EGFP-labeled cell
bodies in the dLGN at locations corresponding retinotopically
to the V1 injection sites of the rAAV2/7-CaMKIIα1.3 vector.
The degree of retrograde labeling was rather low. Injections
Fig. 14 Semiquantitative summary of the transduction results in M10 and M37. This figure shows a semi-
quantitative overview of the results (the spread along the cortical surface and fraction of FP+ neurons) for
each injected vector in the primary visual cortex (M10 and M37) and dorsolateral prefrontal cortex (M37).
Columns 4 and 5 illustrate the spread of FP-labeled cells (black bars) along the anterior–posterior axis
(A-P) and lateral–medial axis (L-M), respectively. Column 5 represents the product of columns 3 and 4
(two-dimensional spread). Column 6 shows the percentage of EGFP+ neurons at the injection site
(300 μm in L-M direction) for individual layers. Column “PV+” shows the percentage of parvalbu-
mine-positive labeled EGFP+ neurons. The last column (LGN) shows anterograde (A)- or retrograde
(R) transduction capability in the LGN as a result of vector injections in V1. Numbers between brackets
correspond to the mean values across monkeys (when available).
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of the rAAV2/7-CaMKIIα0.4, rAAV2/5-CaMKIIα0.4, rAAV2/
8-CaMKIIα0.4, and rAAV2/7-enhSyn1 vectors in V1 resulted
only in anterogradely FP-labeled axons in retinotopically match-
ing regions of the dLGN. The differences in retro-and anterog-
rade transduction capacities in the dLGN may be related to the
laminar variations in transduction observed in area V1 using the
various vectors in the present study. Thalamocortical axons ter-
minate mainly in layer IV;80 hence, good transduction of that
layer should be required for optimal retrograde labeling in
the LGN. Conversely, feedback from V1 to the LGN mainly
originates in layer VI; thus, efficient transduction in the deepest
layer after V1 injections must be a prerequisite for good ante-
rograde labeling in the thalamus.
4.4 Transduction Efficiencies are Area Dependent
We found laminar differences in the transduction patterns in two
neocortical areas (V1 and prefrontal cortex) of the same mon-
key, even when injecting the same viral vector (Fig. 13). Hence,
as expected, the transduction pattern of rAAV vectors also
depends on the targeted area. This suggestion is corroborated
by the apparent discrepancy between our results and those
obtained in primate SN using the same serotype.30 The lack
of FP+ neurons after injecting a CMV construct, however,
was observed in the two neocortical areas. This could indicate
that the aforementioned neural toxicity caused by CMV-driven
constructs affects all cortical regions.
4.5 Limitations
4.5.1 Titer does not explain differences in neuronal trans-
duction patterns
In the present study, a similar volume was injected for all vector
constructs. Several of the viral vector constructs, such as
rAAV2/7-CaMKII0.4, rAAV2/8-CaMKII0.4 and rAAV2/9-
CaMKII0.4, had almost equal genomic titers (2.6, 2.8, and
3.1 E12 gc∕ml, respectively). These constructs, however,
resulted in markedly different numbers of transduced cells
and yielded pronounced differences in the spreads of the trans-
duction patterns along the cortical sheet (see Fig. 14). The func-
tional titer essay also argues against genomic titer being an
explanatory factor for the observed differences in FP expression
patterns (Fig. 11). In addition, similar results with identical viral
vectors were found in the mouse visual cortex.23 We, therefore,
suggest that the main factors driving the variations in transduc-
tion efficiencies are the serotype, the promoter, and the injected
cortical area.
4.5.2 Sample size
Although this study provides useful insights into the transduc-
tion capacity of viral vectors in primates, it has its limitations.
Sample size was low (i.e., multiple injections were only per-
formed in one animal) and differences in time between injection
and perfusion could have produced variations in transductional
profiles. Optimal timing for transduction and expression of
rAAV may vary according to viral vector, injection area, and
species.81 Nevertheless, previous results in monkeys showed
a stable expression of AAV2 after 30 days.39 Although a staining
for inflammatory responses was not performed in this study,
obvious inflammatory tissue damage was not discernable.
Correspondingly, a comparison of blood samples taken from
M37 before and after injection did not reveal any immune
responses.
5 Conclusion
The present study compared NeuN tropism of rAAVs in
macaque cortex. Our results illustrated that different rAAV con-
structs (various recombinant AAV vectors in combination with
different promoters) yield distinct transgene expression patterns
in terms of spread, laminar distribution, cell specificity, and
retrograde transduction capacities. The comparison of multiple
viral vector systems within the present study and across previ-
ously published studies revealed that transduction patterns of
viral vector systems depend on (1) the serotype, (2) the promoter
sequence, and (3) the targeted area. Given the variability in
transduction efficiency obtained using various rAAV constructs,
we advise performing histological checks in each viral vector-
based experiment. More provocatively, these results indicate
that by selecting the appropriate combination of vector and pro-
moter, one may target specific NeuN circuits within primate
striate cortex, confined to specific layers and types of neurons.
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